勒维体痴呆症的亚型:临床特征,生存率和阿波脂蛋白E效应
Alya Gharbi1,2,3, Amina Nasri1,2,3, Ikram Sghaier1,2,3
1Neurology Department, Razi University Hospital, Tunis, Tunisia.
Journal of Alzheimer's disease reports
|December 25, 2023
概括
这项研究将痴呆症与莱维体 (DLB) 亚型进行了比较,发现了临床差异,但没有对生存的影响. 然而,早期记忆问题和男性性别与DLB患者的预后较差有关.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 老年学是一门学科.
背景情况:
- 勒维体痴呆症 (DLB) 是一种进展性神经退行性疾病,具有多种临床表现.
- 有限的研究详细介绍了DLB的临床异质性和亚型.
研究的目的:
- 根据最初的症状来比较DLB的临床亚型.
- 研究Apolipoprotein E (APOE) 基因对DLB亚型和患者结局的影响.
主要方法:
- 将268名DLB患者分为非运动发病 (NMO-DLB),运动发病 (MO-DLB) 和混合发病 (MXO-DLB) 组.
- 分析了临床特征,APOE基因型关联,以及各亚型的生存率.
主要成果:
- 视觉幻觉在MXO-DLB中更频繁;注意力障碍较少.
- 在MXO-DLB中,APOE ε4与较早的跌倒和额叶综合征有关.
- 在DLB亚型之间没有观察到MMSE或FAB下降或整体存活率的显著差异.
结论:
- DLB亚型表现出一些明显的临床特征,APOE ε4可能会影响混合发病的DLB的特定症状.
- 临床DLB亚型似乎不会影响生存率.
- 初始记忆障碍和男性性别成为DLB中较短生存时间的重要预测因素.
相关概念视频
Dementia
115
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
115
Alzheimer's Disease: Overview
492
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
492
Parkinson's Disease: Overview
554
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
554
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Neural Regulation
39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K


